Overview
Arcus Q2 2025 revenue rises sharply, beating analyst expectations, per LSEG data
Co reports strong cash position of $927 mln to support pipeline advancement
Arcus initiates key trials, with upcoming data presentations planned for fall 2025
Outlook
Arcus expects 2025 GAAP revenue between $225 mln and $235 mln
Company anticipates R&D expenses to decline starting Q4 2025
Arcus has sufficient funds to support ongoing trials through pivotal readouts
Company expects more mature ARC-20 data in fall 2025
Result Drivers
REVENUE INCREASE - Driven by cumulative catch-up relating to pausing future development of etrumadenant and Gilead's license return
PIPELINE ADVANCEMENT - Initiation of PEAK-1 and eVOLVE-RCC02 trials for casdatifan in ccRCC
STRONG CASH POSITION - $927 mln in cash and equivalents to support pipeline progress
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $152 mln | $31.50 mln (8 Analysts) |
Q2 Operating Expenses | $168 mln | ||
Q2 Operating Income | -$8 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Arcus Biosciences Inc is $26.00, about 63.3% above its August 5 closing price of $9.55
Press Release: ID:nBw68qpwwa
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.